Company: CMND
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001213900-25-117534
Chunk: 21

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 21
---
 Report generally, which is incorporated by reference into this prospectus.             |

Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Important factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this prospectus or any accompanying prospectus supplement. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements.

Further, any forward-looking statement speaks only as of the date on which it is made. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See “Where You Can Find More Information.”

<div align='center'>S-10

CAPITALIZATION</div>

The following table sets forth our cash and our capitalization as of July 31, 2025:

| ● | on                   
 an actual basis; and |

| ● | on                                                                                                                                             
 pro forma basis, giving effect to the issuance of (i) Promissory Notes                                                                         
 in the aggregate principal amount of $2.5 million, of which an aggregate of $2.5 million of outstanding amounts due under the Promissory       
 Notes were converted into 5,171,460 Common Shares at conversion prices between $0.251 and $0.818, (ii) the issuance and sale of 3,942,365      
 Common Shares and/or pre-funded warrants in the First November 2025 Offering at a public offering price of $0.20 per Common Share and          
 $0.1999 per pre-funded warrant for net proceeds of $738,000, after deducting offering expenses payable by us, (iii) the issuance and sale      
 of 5,509,768 Common Shares